HomeNewscoronavirusICMR pitches for pooling samples for COVID-19 testing in areas with less than 2% positive cases

ICMR pitches for pooling samples for COVID-19 testing in areas with less than 2% positive cases

"It has been demonstrated that performing real-time PCR for COVID-19 by pooling 5 samples of TS/NS is feasible when the prevalence rates of infection are low," the council's advisory says.

April 14, 2020 / 18:25 IST
Story continues below Advertisement

Indian Council of Medical Research (ICMR), the apex medical body, released an advisory for using pooled samples to increase the capacity of laboratories to screen more samples using molecular testing for COVID-19 and for the purpose of surveillance.

A pooled testing algorithm involves the reverse transcription polymerase chain reaction (RT-PCR) screening of multiple individual patient samples pooled together. If the test is positive, all persons are tested individually. This is called pool de-convolution.

Story continues below Advertisement

If all individual samples in a negative pool are regarded as negative, it results in substantial cost savings when a large proportion of pools tests negative.

This method can greatly enhance the capacity to test in a low-resources setting, as RT-PCR test is reliable but not scalable. Also, when positive cases are still low, it may help to use the pooled samples for screening.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show